Evidence map›Paper›PMID 22069763›Full record

ArticleToxins2011

Role of phospholipase A(2) in retrograde transport of ricin.

Tove Irene Klokk, Anne Berit Dyve Lingelem, Anne-Grethe Myrann, Kirsten Sandvig

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Tove Irene KlokkCentre for Cancer Biomedicine, Department of Biochemistry, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway. tove.irene.klokk@rr-research.no
Anne Berit Dyve Lingelem
Anne-Grethe Myrann
Kirsten Sandvig
Oslo University Hospital · NONorwegian Cancer Society · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ricin is a protein toxin classified as a bioterror agent, for which there are no known treatment options available after intoxication. It is composed of an enzymatically active A-chain connected by a disulfide bond to a cell binding B-chain. After internalization by endocytosis, ricin is transported retrogradely to the Golgi and ER, from where the ricin A-chain is translocated to the cytosol where it inhibits protein synthesis and thus induces cell death. We have identified cytoplasmic phospholipase A(2) (PLA(2)) as an important factor in ricin retrograde transport. Inhibition of PLA(2) protects against ricin challenge, however the toxin can still be endocytosed and transported to the Golgi. Interestingly, ricin transport from the Golgi to the ER is strongly impaired in response to PLA(2) inhibition. Confocal microscopy analysis shows that ricin is still colocalized with the trans-Golgi marker TGN46 in the presence of PLA(2) inhibitor, but less is colocalized with the cis-Golgi marker GM130. We propose that PLA(2) inhibition results in impaired ricin transport through the Golgi stack, thus preventing it from reaching the ER. Consequently, ricin cannot be translocated to the cytosol to exert its toxic action.

Indexed as

Cell Line, TumorChemical Warfare AgentsChlorobenzoatesCinnamatesEndocytosisEndoplasmic ReticulumEnzyme InhibitorsHumansNaphthalenesortho-AminobenzoatesPhospholipase A2 InhibitorsPhospholipases A2Protein TransportPyronesRicintrans-Golgi Network2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-oneChemical Warfare AgentsChlorobenzoatesCinnamatesEnzyme InhibitorsNaphthalenesortho-AminobenzoatesPhospholipase A2 InhibitorsPhospholipases A2PyronesRicinGolgiphospholipase A2retrograde transportricintoxin

Identifiers

PMID22069763
PMCPMC3202871
OpenAlexW2005386870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.